UK court overturns Genentech patent, cites Brexit in CJEU referral
01-03-2019
sprng23 / iStockphoto.com
An opinion on whether a supplementary protection certificate can be granted to an owner of a drug patent when the marketing authorisation is held by a third party is overdue, lawyers told LSIPR.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Genentech, Eli Lilly, Court of Justice of the European Union, English High Court, marketing authorisation, supplementary protection certificate
